In addition, in a rat model of rotator cuff tendinopathy, we provide evidence that IL-17A blockade with an anti-IL-17A mAb leads to a reversal of tendon tissue inflammatory and degenerative changes and to the restoration of impaired tendon function, proposed to be the underlying biological mechanisms of the clinical symptom relief by secukinumab in human early-stage tendinopathy. Here, IL17A is linked to disease of the tendon.